Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
about
Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study.Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions.Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.The year in cardiology 2016: peripheral circulation.2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Feasibility and 1-Year outcomes of subintimal revascularization with supera® stenting of long femoropopliteal occlusions in critical limb ischemia: The "Supersub" Study.Direct Stenting in Patients with Acute Lower Limb Arterial Occlusions: Immediate and Long-Term Results.Eluvia™ peripheral stent system for the treatment of peripheral lesions above the knee.Outcomes of Popliteal-To-Distal Bypass Combined with Femoropopliteal Artery Endovascular Treatment for Critical Limb Ischemia.Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system.Penetration rate of the placement of a drug-eluting stent for the treatment of superficial femoral artery lesions in Japan.New Innovations in Drug-Eluting Stents for Peripheral Arterial Disease.Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery.Comparison of treatment strategies for femoro-popliteal disease: A network meta-analysis.Critical limb ischemia update and the evolving role of drug-elution technologies.Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.Bypass versus endovascular intervention for healing ischemic foot wounds secondary to tibial arterial disease.A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.Commentary: Self-Expanding Stentys System for Significant Infrapopliteal Stenoses: Rainbow Six?Pathophysiological Significance of Velocity-Based Microvascular Resistance at Maximal Hyperemia in Peripheral Artery Disease.Drug-delivering endovascular treatment versus angioplasty in artery occlusion diseases: a systematic review and meta-analysis.Real-World Comparison of Drug-Eluting and Bare-Metal Stents in Superficial Femoral Artery Occlusive Disease with Trans-Atlantic Intersociety Consensus B Lesions: A 2-Year, Single-Institute Study.When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease?2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Refractory Vascular Wall Healing after Paclitaxel-Coated Nitinol Stent Implantation in the Femoropopliteal Artery: A High-Resolution Angioscopic Assessment
P2860
Q37598199-DA6DFC28-C825-4D78-8DB9-2CC1C1CF4EE1Q38372419-A4F22426-62FE-4A03-B654-F86545B41E41Q38795000-30481C59-2FBF-428F-A2D7-61F49C732AF1Q38964918-32E62714-B557-4795-9467-43002A0BE9E3Q39007236-7B3B3680-9215-42E3-B9A6-5BB88F43EC7AQ39174616-29942E6D-C622-4A38-9440-2FB777C81564Q39202829-C31841B1-D871-4A79-A838-8CF18EA02CBFQ39435685-457B2131-ACEF-4F84-81E8-0DCEA80AF9E9Q44938029-563AA605-9C29-4AAB-9AA7-57A535F65EEDQ46611491-12975639-891B-410E-8266-3F40C8368017Q47779815-EE75B476-67B5-490E-B701-A0380CFCEACAQ47806000-C92D834C-CDBC-4D71-A5B7-9476BAD3350EQ47905623-9AACFC40-07BC-48E1-995B-BD8CB322A80EQ48247913-240C0B4D-416D-4FA9-B24A-A280CFAA3745Q48595521-468F4AF2-BC69-498C-A530-25FF082BD2A0Q49231343-46CCA7A2-5911-4956-AFCD-DD8E8DCA3DDCQ49835658-72AFF24F-1AA5-4D89-B900-E41F7BD70D34Q50034331-81A49BE4-3CFA-426A-8BA5-CC9A018FF335Q50662064-40236249-EA9F-474E-9FC5-2DE128A1C520Q50743569-C0387624-6B27-48A2-9984-44B70F9CCB5EQ51746301-C98A0FD5-EFFC-475F-BD6C-BDAF1207C137Q51823045-2959BF5A-C333-4D2E-BEBB-B6AD3C95C7D9Q52592991-DECF2500-BCC4-4BAE-BDDB-E4D140771A17Q55127307-15A03AC3-334F-4EC1-A836-FC7C7EF18750Q57621177-E22C0916-45C0-41E4-B657-1C96EED0908CQ58550841-04A93703-8B5B-47AF-B8B6-A3376642B75F
P2860
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@ast
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@en
type
label
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@ast
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@en
prefLabel
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@ast
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@en
P2093
P2860
P1433
P1476
Durable Clinical Effectiveness ...... he Zilver PTX Randomized Trial
@en
P2093
Anthony O Ragheb
Erin E O'Leary
Gary M Ansel
H Bob Smouse
Lindsay S Machan
Michael D Dake
Michael R Jaff
Richard R Saxon
Scott A Snyder
Takao Ohki
P2860
P304
1472-83; discussion 1483
P356
10.1161/CIRCULATIONAHA.115.016900
P407
P577
2016-03-11T00:00:00Z